Action KRBP KIROMIC BIOPHARMA, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Kiromic BioPharma, Inc.

Actions

KRBP

US4976342042

Marché Fermé - OTC Markets
Autres places de cotation
 18:16:23 01/07/2024 		Varia. 5j. Varia. 1 janv.
2 USD -8,68% Graphique intraday de Kiromic BioPharma, Inc. -20,00% +129,89%
20/06 Kiromic BioPharma, Inc. fait le point sur son essai clinique Deltacel-01 CI
29/05 Kiromic BioPharma, Inc. rapporte des resultats favorables a six semaines chez le quatrieme patient de l'essai clinique Deltacel-01 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Provides Updates on Its Deltacel-01 Clinical Trial
Kiromic Biopharma, Inc. Issues 25% Senior Secured Convertible Promissory Note
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
Kiromic BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. announced that it has received $2 million in funding
EARLY EFFICACY RESULTS SHOW PRIMARY LUNG TUMOR STABILIZATION AND COMPLETE DISAPPEARANCE OF BRAIN METASTASES IN SECOND PATIENT IN KIROMIC BIOPHARMA'S DELTACEL-01 CLINICAL TRIAL
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma’s Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Kiromic BioPharma : Corporate Presentation
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action KRBP
  4. Actualités Kiromic BioPharma, Inc.
  5. Autres langues